GSK(GSK)
GSK
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue Avg | $34.37B | $36.17B | $37.25B | $38.55B | $37.95B |
| Low | $34.13B | $33.86B | $36.09B | $37.35B | $36.77B |
| High | $34.59B | $37.30B | $38.35B | $39.69B | $39.07B |
| EBITDA Avg | $11.52B | $12.12B | $12.48B | $12.92B | $12.71B |
| Low | $11.43B | $11.34B | $12.09B | $12.51B | $12.32B |
| High | $11.59B | $12.49B | $12.85B | $13.30B | $13.09B |
| EBIT Avg | $9.43B | $9.92B | $10.22B | $10.57B | $10.41B |
| Low | $9.36B | $9.29B | $9.90B | $10.24B | $10.08B |
| High | $9.49B | $10.23B | $10.52B | $10.89B | $10.72B |
| Net Income Avg | $3.70B | $4.12B | $4.40B | $4.52B | $4.61B |
| Low | $3.57B | $3.86B | $4.02B | $4.34B | $4.42B |
| High | $3.84B | $4.38B | $4.77B | $4.69B | $4.79B |
| EPS Avg | $3.62 | $3.97 | $4.16 | $4.39 | $4.48 |
| Low | $3.47 | $3.75 | $3.91 | $4.21 | $4.30 |
| High | $3.73 | $4.25 | $4.64 | $4.56 | $4.65 |
| Analysts (Rev / EPS) | 12 / 5 | 13 / 6 | 16 / 8 | 15 / 6 | 15 / 6 |
| Metric | Q2 2026 | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|---|
| Revenue Avg | $8.38B | $9.06B | $9.10B | $8.05B | $8.62B | $9.32B | $9.37B |
| Low | $7.77B | $8.61B | $8.84B | $7.82B | $8.37B | $9.05B | $9.10B |
| High | $8.67B | $9.48B | $9.40B | $8.32B | $8.91B | $9.62B | $9.68B |
| EBITDA Avg | $2.81B | $3.03B | $3.05B | $2.70B | $2.89B | $3.12B | $3.14B |
| Low | $2.60B | $2.89B | $2.96B | $2.62B | $2.80B | $3.03B | $3.05B |
| High | $2.90B | $3.18B | $3.15B | $2.79B | $2.98B | $3.22B | $3.24B |
| EBIT Avg | $2.30B | $2.48B | $2.50B | $2.21B | $2.36B | $2.56B | $2.57B |
| Low | $2.13B | $2.36B | $2.42B | $2.14B | $2.30B | $2.48B | $2.50B |
| High | $2.38B | $2.60B | $2.58B | $2.28B | $2.44B | $2.64B | $2.66B |
| Net Income Avg | $1.89B | $2.21B | $1.15B | $1.96B | $1.95B | $2.38B | $1.15B |
| Low | $1.86B | $2.07B | $1.11B | $1.89B | $1.87B | $2.29B | $1.11B |
| High | $1.94B | $2.30B | $1.20B | $2.05B | $2.03B | $2.48B | $1.20B |
| EPS Avg | $0.93 | $1.08 | $0.57 | $0.96 | $0.96 | $1.17 | $0.57 |
| Low | $0.91 | $1.02 | $0.54 | $0.93 | $0.92 | $1.12 | $0.55 |
| High | $0.95 | $1.13 | $0.59 | $1.01 | $1.00 | $1.22 | $0.59 |
| Analysts (Rev / EPS) | 5 / 3 | 5 / 3 | 2 / 1 | 2 / 1 | 2 / 1 | 2 / 1 | 2 / 1 |